Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment
Authors:
- Xiaolan FengXFXiaolan Feng
- Laurie TononLTLaurie Tonon
- Haocheng LiHLHaocheng Li
- Elodie DarboEDElodie Darbo
- Erin PleasanceEPErin Pleasance
- Nicolas MacagnoNMNicolas Macagno
- Armelle DufresneADArmelle Dufresne
- Mehdi BrahmiMBMehdi Brahmi
- Julien BollardJBJulien Bollard
- Francoise DucimetièreFDFrancoise Ducimetière
- Marie KaranianMKMarie Karanian
- Alexandra MeurgeyAMAlexandra Meurgey
Open Access
Abstract
Purpose: To investigate the immune biomarker in Leiomyosarcoma (LMS), which is rare and recognized as an immune cold cancer showing a poor response rate (<10%) to immune checkpoint inhibitors (ICIs). However, durable response and clinical benefit to ICIs has been observed in a few cases of LMS, including, but not only, LMS with tertiary lymphoid structure (TLS) structures. Patients and methods: We used comprehensive transcriptomic profiling and a deconvolution method extracted from RNA-sequencing gene expression data in two independent LMS cohorts, the International Cancer Genome Consortium (ICGC, N = 146) and The Cancer Genome Atlas (TCGA, N = 75), to explore tumor immune microenvironment (TIME) in LMS. Results: Unsupervised clustering analysis using the previously validated two methods, 90-gene signature and Cell-type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT), identified immune hot (I-H) and immune high (I-Hi) LMS, respectively, in the ICGC cohort. Similarly, immune active groups (T-H, T-Hi) were identified in the TCGA cohort using these two methods. These immune active (“hot”) clusters were significantly associated, but not completely overlapping, with several validated immune signatures such as sarcoma immune class (SIC) classification and TLS score, T cell inflamed signature (TIS) score, immune infiltration score (IIS), and macrophage score (M1/M2), with more patients identified by our clustering as potentially immune hot. Conclusions: Comprehensive immune profiling revealed a subset of LMS with a distinct active (“hot”) TIME, consistently associated with several validated immune signatures in other cancers. This suggests that the methodologies that we used in this study warrant further validation and development, which can potentially help refine our current immune biomarkers to select the right LMS patients for ICIs in clinical trials.Keywords
Funding Information
- Institut Thematique Multiorganismes (ITMO) Cancer
- Claudius Regaud Institute
This publication has 48 references indexed in Scilit:
- TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packagesF1000Research, 2016
- RNA sequencing validation of the Complexity INdex in SARComas prognostic signatureEuropean Journal of Cancer, 2016
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA dataNucleic Acids Research, 2015
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Immunohistochemical expression of estrogen and progesterone receptors and outcomes in patients with newly diagnosed uterine leiomyosarcomaGynecologic Oncology, 2012
- Trends in survival for patients with metastatic soft‐tissue sarcomaCancer, 2010
- Prognostic Significance of Macrophage Infiltration in LeiomyosarcomasClinical Cancer Research, 2008
- The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.2006
- Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProceedings of the National Academy of Sciences, 2005
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984